服务平台拥有丰富的技术服务经验，一流的仪器设备，先进的检测手段和严格的质量控制体系，力求为全球药物研发机构提供优质高效的技术服务
产品介绍 Apremilast, also known as CC-10004, is a novel and potent small-molecule inhibitor of phosphodiesterase 4 (PDE4), a key enzyme involved in cyclic adenosine monophosphate (cAMP) degradation and cytokine production of inflammatory cells.
询价产品介绍 Apoptosis Inhibitor is a cell-permeable inhibitor of apoptosis induction. It does not directly inhibit caspase-3, but its effects are attributable to the inhibition of caspase-3 activation.
询价产品介绍 Apoptosis Inhibitor is a cell-permeable inhibitor of apoptosis induction. It does not directly inhibit caspase-3, but its effects are attributable to the inhibition of caspase-3 activation.
询价产品介绍 Apoptosis Inhibitor is a cell-permeable inhibitor of apoptosis induction. It does not directly inhibit caspase-3, but its effects are attributable to the inhibition of caspase-3 activation.
询价背景介绍 Apoptosis Activator 2 is a cell-permeable indoledione compound that activates caspases in a cytochrome c-dependent manner and induces apoptosis in tumor cells by promoting the oligomerization of Apaf-1 into the mature apoptosome. Its cytotoxicity is selective towards tumor cells (IC50 < 10 µM for Jurkat, Molt-4, and CCRF-CEM). Apoptosis Activator 2 shows little or no effect on non-tumor cells or cells that are deficient in caspase-3 or Apaf-1 (IC50 > 40 µM). Through the induction of apoptosis, Apoptosis Activator 2 notably induces caspase-3 activation, PARP cleavage and DNA fragmentation. Moreover, this induction of apoptosis only occurs in tumor cell lines (such as breast, lung, colon, and epidermal cancer cell lines). 产品介绍 Apoptosis Activator 2 is a small, cell permeable activator of caspase-3. Apoptosis Activator 2 induces apoptosis specifically in tumor cell lines, but not normal cell lines, with IC50 value of about 4 µM.
询价背景介绍 Apoptosis Activator 2 is a cell-permeable indoledione compound that activates caspases in a cytochrome c-dependent manner and induces apoptosis in tumor cells by promoting the oligomerization of Apaf-1 into the mature apoptosome. Its cytotoxicity is selective towards tumor cells (IC50 < 10 µM for Jurkat, Molt-4, and CCRF-CEM). Apoptosis Activator 2 shows little or no effect on non-tumor cells or cells that are deficient in caspase-3 or Apaf-1 (IC50 > 40 µM). Through the induction of apoptosis, Apoptosis Activator 2 notably induces caspase-3 activation, PARP cleavage and DNA fragmentation. Moreover, this induction of apoptosis only occurs in tumor cell lines (such as breast, lung, colon, and epidermal cancer cell lines). 产品介绍 Apoptosis Activator 2 is a small, cell permeable activator of caspase-3. Apoptosis Activator 2 induces apoptosis specifically in tumor cell lines, but not normal cell lines, with IC50 value of about 4 µM.
询价背景介绍 Anagrelide is a FDA-approved drug for the treatment of essential thrombocythemia. It is originally identified as a potential inhibitor of platelet aggregation. Anagrelide selectively affects thrombocytes while shows no significant effect on white blood cells, erythrocytes, or coagulation. Anagrelide is a potent inotropic agent for dogs with remarkable vasodilatory activity. Additionally, anagrelide can reduce renal blood flow. Furthermore, anagrelide has shown to play roles in other chronic myeloproliferative disorders, such as polycythemia vera, chronic myeloid leukemia and agnogenic myeloid metaplasia. Anagrelide has some side effects involving headache, diarrhea, edema, palpitations, and abdominal pain. 产品介绍 Anagrelide is a selective thrombocytopenic agent that inhibits PDE3. It also has been used in the treatment of chronic myeloid leukemia.
询价背景介绍 Anagrelide is a FDA-approved drug for the treatment of essential thrombocythemia. It is originally identified as a potential inhibitor of platelet aggregation. Anagrelide selectively affects thrombocytes while shows no significant effect on white blood cells, erythrocytes, or coagulation. Anagrelide is a potent inotropic agent for dogs with remarkable vasodilatory activity. Additionally, anagrelide can reduce renal blood flow. Furthermore, anagrelide has shown to play roles in other chronic myeloproliferative disorders, such as polycythemia vera, chronic myeloid leukemia and agnogenic myeloid metaplasia. Anagrelide has some side effects involving headache, diarrhea, edema, palpitations, and abdominal pain. 产品介绍 Anagrelide is a selective thrombocytopenic agent that inhibits PDE3. It also has been used in the treatment of chronic myeloid leukemia.
询价背景介绍 Alvespimycin hydrochloride is the hydrochloride salt of alvespimycin, an analogue of the antineoplastic benzoquinone antibiotic geldanamycin. Alvespimycin binds to HSP90, a chaperone protein that aids in the assembly, maturation and folding of proteins. Subsequently, the function of Hsp90 is inhibited, leading to the degradation and depletion of its client proteins such as kinases and transcription factors involved with cell cycle regulation and signal transduction. 产品介绍 Alvespimycin HCl, also known as 17-DMAG, is a potent, water-soluble HSP90 inhibitor. Alvespimycin has diverse anti-tumor actions and has potential in treating a number of different types of cancers, including ovarian, prostate, melatnoma, non-small-cell lung cancer, and several leukemias (chronic lymphocytic, acute myeloid). This compound also suppresses inflammation by interfering with signaling through the NF-κB pathway.
询价
